플라이언트 테라퓨틱스(PLRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.07 (-0.93%), 시가총액 $0.07B, 52주 범위 $1.09 ~ $1.87.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
플라이언트 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
플라이언트 테라퓨틱스의 현재 주가는 $1.07 (-0.93%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
플라이언트 테라퓨틱스의 시가총액은 약 $0.07B입니다.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product c